– ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months
– The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage
– New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immuno-oncology
ALLSCHWIL, Switzerland, March 29, 2022 /PRNewswire/ — BioCopy AG introduces ValidaTe, an innovative, proprietary platform based on microarrays for the highly parallelized screening of drug candidates for T-cell therapy. ValidaTe is now available to biopharmaceutical companies.
With ValidaTe, about 5,000 protein-protein binding interactions are characterized simultaneously in one hour on one chip. Thus, ValidaTe chips can mirror the complexity of the human immune system. Drug candidates can be identified and drug leads can be validated instantly by screening thousands of peptide-HLA complexes placed on a thumbnail-sized surface. This parallel measurement of binding interactions is based on a proprietary label-free detection technology, which delivers highly accurate and detailed time-resolved kinetic data sets.
ValidaTe significantly shortens the time-consuming and laborious drug discovery and validation phase for novel T-cell therapies. It can provide a decisive head start in drug development, setting new benchmarks for speed and efficiency.
With this ground-breaking technology, biopharmaceutical companies can characterize and validate the efficacy and safety of T-cell drug candidates within days instead of months. The ValidaTe array can be tailored to measure the active structures of individual drug candidates for T-cell therapeutics, such as TCR-bispecifics or TCR-T-cells.
Product enhancements in 2022 include an expanded array capacity of 10,000 spots and cell-based formats.
For further information on ValidaTe visit: https://www.biocopy.com/en/t-cell-therapy/, for exemplary binding curves, see https://vimeo.com/manage/videos/690853985.
BioCopy provides high-throughput analyses to characterize immune responses for drug discovery. At BioCopy, we are convinced that this holds the key to future medicine, especially for immunotherapeutics and novel vaccines. Founded as a university spin-off in 2016, BioCopy is a multinational company headquartered in Switzerland with a large and modern R&D facility in Germany.
Photo – https://mma.prnewswire.com/media/1774835/BioCopy_Microarray.jpg
Logo – https://mma.prnewswire.com/media/1558072/BioCopy_Logo.jpg
Dr. Claudia Duppé
+49 151 62986930
View original content to download multimedia:https://www.prnewswire.com/news-releases/biocopy-ag-presents-validate-a-novel-ultra-fast-screening-technology-to-significantly-speed-up-drug-discovery-in-t-cell-therapy-301511986.html
SOURCE BioCopy AG
Neither of the obstacles I'll discuss today are insurmountable, but they both pose substantial risk to Novavax's stock, so let's take a look. The biggest reason why Novavax investors need to be careful right now is that the U.S. Food and Drug Administration (FDA) hasn't approved its coronavirus vaccine yet despite having its application packet since Jan. 31. While the FDA assented to similar requests for Emergency Use Authorization (EUA) from competitors like Pfizer and Moderna within a handful of weeks, the process is dragging on with Novavax's candidate, and it's unclear why.
Wednesday is going to be a very big day for folks with neurodegenerative disorders and a clinical-stage biopharmaceutical company called Amylyx Pharmaceuticals (NASDAQ: AMLX). On March 30, the FDA is meeting with independent neurologists to discuss the company's experimental treatment for amyotrophic lateral sclerosis (ALS). Each year, around 6,000 American adults are diagnosed with ALS after complaining about muscle weakness.
What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold shoulder. On the positive side, the pennies offer the best cost of entry in the stock market. Anyone who truly believes the adage ‘buy low and sell high’ simply can’t ignore the pennies, because this is where you can buy low. And because the sha
Both Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) benefited Tuesday from a timely reminder that the coronavirus pandemic isn't yet over, and certain patient populations remain vulnerable. The stocks of the two companies rose on the Food and Drug Administration (FDA) amending its authorizations for the pair's COVID vaccines. Moderna enjoyed a nearly 4.4% boost to its share price, while BioNTech closed the day 3.6% higher.
Yahoo Finance Live anchors discuss the latest COVID-19 vaccine news.
Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said that the trial met its primary objective of safety. All efficacy endpoints were exploratory as the study was not powered to detect treatment differences. In the study of 63 randomized patients, 31% were admitted to the ICU before initiation of treatment. The WHO ordinal scale indicated severe dis
The Food and Drug Administration granted marketing approval on Tuesday for Tlando, an oral testosterone replacement therapy developed by a New Jersey specialty pharmaceutical company. Antares Pharma (NASDAQ: ATRS) of Ewing plans to launch the prescription medicine during the second quarter of this year. The FDA approval had little impact on the company's shares, which were trading up less than 1% at $4.14 per share in late morning trading.
Vaccine stocks jumped Tuesday after the FDA authorized another round of Covid booster shots for people age 50 and older.
Pfizer Inc. on Tuesday said a second Phase 3 study of its recently acquired investigational drug etrasimod met the main endpoints in the treatment of moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.
Biogen will stop developing a drug to treat a severe neurodegenerative disease, as it did not show sufficient benefit when tested in trials.
The Food and Drug Administration authorized a fourth dose, or second booster shot, of the Pfizer and Moderna COVID-19 vaccines for adults age 50 and older and immunocompromised groups.
The BA.2 variant isn't yet dominant in the U.S., but theFDA has limited the use of a Covid-19 monoclonal antibody therapy thought to be ineffective against it.
It seems the FDA isn't going to approve the company's ALS drug before an ongoing phase 3 trial produces evidence of efficacy.
U.S. regulators authorized a second booster dose of Pfizer Inc and BioNTech SE's COVID-19 vaccine for people 50 and older due to concerns about waning immunity in the age group, the drugmakers said on Tuesday. The U.S. Food and Drug Administration also authorized the second booster dose of the vaccine for people aged 12 and older with compromised immune systems. The new boosters – a fourth round of shots – to be administered at least four months after the third dose are intended to offer more protection against severe disease and hospitalization, the companies said.
The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK and Vir said they are preparing a data package to support a higher dose for sotrovimab for the BA.2 subvariant. Related: AstraZeneca
The Lexington-Fayette County Health Department said it will look into offering a second COVID-19 vaccine booster, free of charge, to eligible groups.
The U.S. Food and Drug Administration said Tuesday it has authorized a second booster dose of either the Pfizer/BioNTech or Moderna COVID-19 vaccines for people aged 50 and older. The agency has also authorized a second booster for people aged 12 and older who are immunocompromised and at risk of developing severe illness. The second shot will be administered at least four months after receiving the first booster jab of any authorized or approved COVID vaccine. "Emerging evidence suggests that a
The drug, branded as Fintepla, already has the U.S. approval to treat another form of childhood-onset epilepsy, Davet Syndrome (DS), in patients aged two years and older. LGS causes cognitive dysfunction and frequent seizures that often lead to injury, and UCB's Zogenix unit estimates that about 30,000 to 50,000 people have the syndrome in the United States.
The world's largest randomised study of potential medicines for COVID-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment. "Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe COVID-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial. The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with COVID-19.
The Food and Drug Administration on Tuesday authorized an extra dose of the Pfizer or Moderna vaccine for that age group and for certain younger people with severely weakened immune systems. The Centers for Disease Control and Prevention later recommended the extra shot as an option but stopped short of urging that those eligible rush out and get it right away. Dr. Rochelle Walensky, CDC's director, said it was especially important for older Americans — those 65 and older — and the 50-somethings with chronic illnesses such as heart disease or diabetes to consider another shot.